Physician profile
Stevie Bennett
NPI 1275927634
$2,207.30
in general payments reported to CMS, 2019-2025
31 companies · $275 in 2025
The $275 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $84.14 · 2020: $243 · 2021: $580 · 2022: $348 · 2023: $330 · 2024: $348 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $913 · Education: $40.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $912.61 |
| Education | $40.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $626.69 | 2019-2024 | Lo Loestrin Fe |
| Evofem Biosciences, INC. | $373.22 | 2020-2024 | |
| Mayne Pharma Commercial LLC | $120.30 | 2023-2025 | |
| Millicent US INC | $114.02 | 2023-2025 | Intrarosa, Femlyv |
| Myriad Women'S Health, INC. | $92.59 | 2023 | Myrisk |
| Sage Therapeutics, LLC | $72.02 | 2024-2025 | Zurzuvae |
| Pfizer INC. | $68.13 | 2023-2024 | |
| Therapeuticsmd, INC. | $64.80 | 2020-2022 | |
| Conmed Corporation | $57.99 | 2019-2024 | Airseal, Vcare, Conmed Specimen Retrieval |
| Amgen INC. | $56.36 | 2020-2021 | |
| Minerva Surgical, INC | $55.88 | 2024 | |
| Ethicon US, LLC | $54.78 | 2024-2025 | Ethicon, Dermabond Prineo |
| Shield Therapeutics INC | $43.45 | 2024-2025 | |
| Myovant Sciences INC. | $43.25 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.21 | 2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $36.40 | 2019-2020 | |
| Hologic Sales and Service, LLC | $34.28 | 2024 | Omni Hysteroscope, Novasure, Myosure Tissue Removal Device |
| Astellas Pharma US INC | $31.11 | 2019-2025 | Veozah |
| Coopersurgical, INC. | $28.99 | 2022 | |
| Sumitomo Pharma America, INC. | $25.97 | 2023-2024 | Myfembree |
| Allergan, INC. | $22.78 | 2020 | |
| Merck Sharp & Dohme LLC | $18.90 | 2020 | |
| Boston Scientific Corporation | $18.21 | 2023 | |
| Avion Pharmaceuticals | $16.42 | 2021 | |
| Supernus Pharmaceuticals, INC. | $15.77 | 2025 | Qelbree |
| Novo Nordisk INC | $13.90 | 2023 | |
| Vertical Pharmaceuticals, LLC | $13.48 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.41 | 2019 | |
| Organon LLC | $12.82 | 2025 | Nexplanon |
| Lupin INC. | $11.17 | 2020 | |
| Amag Pharmaceuticals, INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stevie Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.